Sikandar Billal H, Mmagu Obinna
Internal Medicine/Cardiology, University of Maryland Prince George's Hospital Center, Cheverly, USA.
Cardiology, University of Maryland Prince George's Hospital Center, Cheverly, USA.
Cureus. 2021 Feb 6;13(2):e13167. doi: 10.7759/cureus.13167.
The following case involves a 62-year-old female patient suffering from heart failure with reduced ejection fraction (HFrEF) secondary to non-ischemic cardiomyopathy and Graves disease, who developed ventricular fibrillation (VF) after discontinuation of methimazole in preparation for radioiodine ablation. Electrocardiogram (ECG) showed a severely prolonged QTc in the setting of thyrotoxicosis, which significantly improved with high dose methimazole. VF secondary to thyrotoxicosis has rarely been reported and the literature review shows scarce data on its mechanism. Our case demonstrates not only a possible mechanism for the arrhythmia, but also highlights a potential risk factor for it. The report details how discontinuing antithyroid medication leads to VF in our patient and reviews the current literature on antithyroid withdrawal prior to radioiodine ablation therapy. Caution should be taken when discontinuing antithyroid medications in patients with advanced heart failure as potentially lethal ventricular arrhythmias can ensue.
以下病例涉及一名62岁女性患者,患有射血分数降低的心力衰竭(HFrEF),继发于非缺血性心肌病和格雷夫斯病,在为放射性碘消融术停用甲巯咪唑后发生心室颤动(VF)。心电图(ECG)显示在甲状腺毒症情况下QTc严重延长,高剂量甲巯咪唑治疗后明显改善。甲状腺毒症继发的VF鲜有报道,文献综述显示其机制的数据稀缺。我们的病例不仅展示了心律失常的一种可能机制,还突出了其一个潜在危险因素。该报告详细阐述了停用抗甲状腺药物如何导致我们患者发生VF,并回顾了目前关于放射性碘消融治疗前停用抗甲状腺药物的文献。对于晚期心力衰竭患者停用抗甲状腺药物时应谨慎,因为可能会随之发生潜在致命的室性心律失常。